Skip to main content

Table 1 Demographics and disease characteristics

From: Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

  All patients (N = 20)
Age (median, range) in years 59.8 (36.9 to 69.3)
Gender (n, %)
 Male 18 (90.0)
 Female 2 (10.0)
ECOG PS (n, %)
 0 9 (45.0)
 1 11 (55.0)
Time since initial diagnosis (median, range) in days 14 (7–611)
Disease status (n, %)
 Locally advanced 4 (20.0)
 Metastatic 16 (80.0)
Location of the primary tumor (n, %)
 Upper 7 (35.0)
 Middle 6 (30.0)
 Lower 7 (35.0)
TNM staging (n, %)
 T3 3 (15.0)
 T4 11 (55.0)
 Tx 6 (30.0)
 M0 4 (20.0)
 M1 16 (80.0)
 N1 1 (5.0)
 N2 3 (15.0)
 N3 6 (30.0)
 Nx 10 (50.0)
Histology (n, %)
 Poorly differentiated adenocarcinoma 11 (55.0)
 Moderately differentiated adenocarcinoma 5 (25.0)
 Unknown differentiated adenocarcinoma 4 (20.0)
  1. ECOG Eastern Cooperative Oncology Group, T tumor, N node, M metastasis